

McDermott Will & Emery

RECEIVED
CENTRAL FAX CENTER

JUN 21 2007

Boston Brussels Chicago Düsseldorf London Los Angeles Miami Milan
Munich New York Orange County Rome San Diego Silicon Valley Washington, D.C.

FACSIMILE

Date: June 21, 2007

Time
Sent:

To:	Company:	Facsimile No:	Telephone No:
Mail Stop: AMENDMENT	USPTO	571-273-8300	
From:	Atabak R. Royae	Direct Phone:	617.535.4108
E-Mail:	aroyae@mwe.com		
Sent By:		Direct Phone:	
Client/Matter/Tkpr:	068911-0126	Original to Follow by Mail	No
		Number of Pages, Including Cover:	14

Message:

BST99 1525996-1.068911.0060

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copy of this facsimile is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone and return the original message to us at the below address by mail. Thank you.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL AS SOON AS POSSIBLE.

Main Facsimile: 617.535.3800 Facsimile Operator: 617.535.4000

U.S. practice conducted through McDermott Will & Emery
28 State Street Boston, Massachusetts 02109-1775

Telephone: 617.535.4000

PAGE 1/14 * RCVD AT 6/21/2007 3:21:49 PM [Eastern Daylight Time] * SVR:USPTO-EFAX-6/17 * DNIS:2738300 * CSID:617 535 3869 * DURATION (mm-ss):05-06

JUN 21 2007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Babish, et al.
Application No.: 10/557,293
Filing Date: November 18, 2005
Docket Number: 068911-0126
Title: ANTI- INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR
REDUCING INFLAMMATION AND THE TREATMENT OR
PREVENTION OF GASTRIC TOXICITY
Examiner: Not yet assigned
Art Unit: 1654
Confirmation No.: 9021

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Mail Stop: Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571) 273-8300 to the USPTO, on the date indicated below.

Date: June 21, 2007


Jacqueline Andreu**MAIL STOP AMENDMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Enclosed herewith for filing in connection with the above-identified patent application are the following:


- 1) Second Preliminary Amendment (12 pages)

The Commissioner is authorized to charge additional claim fees in the amount \$125.00 for 5 new claims added to this Second Preliminary Amendment, and/or credit any overpayment to Deposit Account Number 50-1133.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP

Dated: June 21, 2007


Atabak R. Royade, Reg. No. 59,037
McDERMOTT WILL & EMERY LLP
28 State Street
Boston, Massachusetts 02109
Telephone: (617) 535-4049
Facsimile: (617) 535-3800

JUN 21 2007

PATENT
Attorney Docket No. 068911-0126


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
J. Babish, *et al.*) Group Art Unit: 1654
)
Application No.: 10/557,293) Examiner: Not Yet Assigned
)
Filed: November 18, 2005)
)
International Filing Date: May 21, 2004) Confirmation No.: 9021
)
For: Anti-Inflammatory Pharmaceutical
Compositions for Reducing
Inflammation and The Treatment or
Prevention of Gastric Toxicity

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted (5710 273-8300 to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Date: June 21, 2007


Jacqueline I. Andreu

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SECOND PRELIMINARY AMENDMENT

Prior to the examination of the above application, please amend this application for a second time as follows:

Amendments to the Claims are reflected in the listing of claims in this paper at page 2.

Remarks/Arguments follow the amendment sections of this paper at page 12.

BST99 1540233-1.068911.0126